This study focuses on HIV prevention in individuals at risk of infection. The research compares two different approaches to pre-exposure prophylaxis (PrEP), which is a preventive treatment that helps protect people from getting HIV. The study evaluates two medications: cabotegravir, which is given as both tablets and long-acting injections, and Truvada, which contains two substances (emtricitabine and tenofovir disoproxil) and is taken as tablets.

The main purpose of the study is to determine how well people maintain their PrEP treatment over time when using either injectable cabotegravir or oral Truvada tablets. The study will last for 24 months, during which participants will receive either cabotegravir (starting with 30 mg tablets followed by 600 mg injections) or Truvada tablets (containing 200 mg emtricitabine and 245 mg tenofovir disoproxil).

Throughout the study, participants will attend regular medical visits where their health will be monitored. These visits will include various health assessments, blood tests, and questionnaires about their experiences with the medication. The study will track how consistently participants use their assigned medication and evaluate its effectiveness in preventing HIV infection.